AEterna Zentaris (NASDAQ:AEZS) Rating Lowered to D at TheStreet

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) was downgraded by investment analysts at TheStreet from a “c-” rating to a “d” rating in a note issued to investors on Thursday, TheStreetRatingsTable reports.

Several other equities analysts have also recently weighed in on AEZS. ValuEngine cut AEterna Zentaris from a “buy” rating to a “hold” rating in a research report on Wednesday, March 27th. Zacks Investment Research lowered AEterna Zentaris from a “buy” rating to a “hold” rating in a research note on Friday, March 15th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $3.17.

Shares of AEterna Zentaris stock opened at $3.02 on Thursday. AEterna Zentaris has a one year low of $1.29 and a one year high of $5.57. The stock has a market cap of $45.21 million, a P/E ratio of 12.08 and a beta of 1.34.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.18). AEterna Zentaris had a negative return on equity of 328.95% and a negative net margin of 666.76%. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $4.20 million. On average, research analysts forecast that AEterna Zentaris will post 1.71 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its holdings in AEterna Zentaris by 232.8% during the first quarter. Renaissance Technologies LLC now owns 110,078 shares of the biopharmaceutical company’s stock worth $512,000 after buying an additional 77,000 shares during the last quarter. AJO LP bought a new position in AEterna Zentaris during the first quarter worth about $1,031,000. Acadian Asset Management LLC boosted its holdings in AEterna Zentaris by 271.2% during the first quarter. Acadian Asset Management LLC now owns 167,222 shares of the biopharmaceutical company’s stock worth $777,000 after buying an additional 122,173 shares during the last quarter. Virtu Financial LLC bought a new position in AEterna Zentaris during the first quarter worth about $179,000. Finally, Jane Street Group LLC bought a new position in AEterna Zentaris during the fourth quarter worth about $30,000. Hedge funds and other institutional investors own 13.67% of the company’s stock.

About AEterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Read More: What are the components of an earnings report?

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.